COMPANY

MOMA Therapeutics

HQ: Cambridge, MA source · momatx.com ↗ · New England

Keywords: oncology Prostate Cancer Pancreas Cancer Breast Cancer Ovarian Cancer Homologous Recombination Deficiency Endometrial Cancer MSI-H Cancer Colorectal Cancer Gastric Cancer dMMR Cancer MOMA-313 MOMA-341

Location: Cambridge, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Jul 16, 2025 Trial start Phase 1: Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors source ↗
Jan 8, 2025 Partnership Partnership / licensing announced Jan 8, 2025. Source: company's own press page. source ↗
Aug 13, 2024 Trial start Phase 1: Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors source ↗

Upcoming milestones

May 31, 2027 (ESTIMATED) · Phase 1 · Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors · NCT06545942
2027-11 (ESTIMATED) · Phase 1 · Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors · NCT06974110

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jan 8, 2025 Partnership / licensing announced Jan 8, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06545942	Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	Aug 13, 2024	May 31, 2027 (estimated)
NCT06974110	Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	Jul 16, 2025	2027-11 (estimated)